Metropolis Healthcare Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts more than Nifty Microcap 250 and 0.9 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Metropolis Healthcare reported strong Q1 FY26 (quarter ended June 30, 2025) results, with consolidated revenue from operations rising about 23% year-on-year to ₹386.06 crore, up from ₹313.36 crore in Q1 FY25. Consolidated profit after tax grew nearly 19% to ₹45.25 crore, while EPS stood at ₹8.70 versus ₹7.41 a year ago. On a standalone basis, revenue grew about 13% to ₹323.63 crore and PAT rose nearly 14% to ₹35.58 crore. Statutory auditor BSR & Co. LLP issued an unmodified (clean) limited review report on both results. The Board also approved a ₹17 crore cash acquisition of Dr. RS Patil's Ambika Pathology Laboratory in Kolhapur, Maharashtra, marking a continued push to expand its regional diagnostics footprint.
Strong double-digit consolidated revenue growth and improved profitability reflect healthy demand for Metropolis's pathology services and a positive start to FY26. The Kolhapur acquisition supports its strategy of building regional mini-reference labs, which could drive future volume and margin gains, though the ongoing income tax dispute (₹3,880 lakhs demand, partly provided for) remains a key watchpoint.